CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects.
Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在过去十年中，针对 PD-1/PD-L1 系统的免疫检查点阻断（ICB）等免疫疗法已经彻底改变了许多疾病的治疗。迄今为止，卵巢癌从这一成功故事中获益甚少。可能的原因包括：与其他肿瘤类型相比突变负荷较低、（新）抗原呈递不充分，以及调节性 T 细胞和肿瘤相关巨噬细胞等免疫抑制性免疫细胞浸润增加。因此，在迄今已完成的临床试验中，对 PD-1/PD-L1 检查点抑制剂的缓解率也低得令人失望，尽管在卵巢癌中也观察到了个别长期缓解。现在的任务是寻找合适的预测性生物标志物，以及确定能够提高卵巢癌免疫原性或克服免疫抑制性耐药机制的 ICB 治疗联合伙伴。本文概述了卵巢癌中的免疫微环境、其对 ICB 效果的影响，并总结了迄今为止关于 ICB 治疗卵巢癌的可用临床试验数据。
In the last decade immunotherapies such as immune checkpoint blockade (ICB) against the PD-1/PD-L1 system have revolutionised the treatment of numerous entities. To date, ovarian cancer has benefited very little from this success story. Possible causes include a rather low mutational burden compared to other tumour types, inadequate presentation of (neo-)antigens, and increased infiltration with immunosuppressive immune cells such as regulatory T cells and tumour-associated macrophages.
In the clinical trials completed to date, the response rates to PD-1/PD-L1 checkpoint inhibitors have therefore been disappointingly low as well, although isolated long-term remissions have also been observed in ovarian cancer.
The task now is to find suitable predictive biomarkers as well as to identify combination partners for ICB therapy that can increase the immunogenicity of ovarian cancer or overcome immunosuppressive resistance mechanisms. This paper provides an overview of the immune milieu in ovarian cancer, its impact on the effect of ICB, and summarises the clinical trial data available to date on ICB in ovarian cancer.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
